-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Poxel SA and its partner Sumitomo Dainippon Pharma have recently announced plans to launch Twymeeg (imeglimin hydrochloride, 500mg tablets) in Japan on September 16, 2021.
In June 2021, Twymeeg was approved in Japan.
Targeting mitochondrial dysfunction, Twymeeg is a new type of oral hypoglycemic drug with a dual mechanism of action.
Twymeeg (imeglimin) is Poxel's first commercialized product
Japanese regulatory approval triggered a milestone payment of 1.
The chemical structure of imeglimin (picture source: Wikipedia)
Imeglimin is a first-in-class drug with a new mechanism of action (MOA) targeting mitochondrial dysfunction, which can improve insulin secretion disorders and insulin sensitivity, both of which It is a key factor leading to type 2 diabetes
In Japan, the regulatory approval of Twymeeg is based on data from the Phase III clinical development project TIMES
Differentiation mechanism of imeglimin
Imeglimin is the first in a new class of chemical substances (Glimins) containing tetrahydrotriazine molecules
Imeglimin can simultaneously target all three key organs (liver, muscle, and pancreas) involved in glucose homeostasis
Note: The original text has been deleted
Original source: Poxel Announces Product Launch in Japan for TWYMEEG as Treatment for Type 2 Diabetes
